Oncology Institute (TOI) Common Equity (2020 - 2025)
Historic Common Equity for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to -$12.3 million.
- Oncology Institute's Common Equity fell 17927.92% to -$12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.3 million, marking a year-over-year decrease of 17927.92%. This contributed to the annual value of $3.6 million for FY2024, which is 9370.63% down from last year.
- Latest data reveals that Oncology Institute reported Common Equity of -$12.3 million as of Q3 2025, which was down 17927.92% from -$9.0 million recorded in Q2 2025.
- Oncology Institute's Common Equity's 5-year high stood at $132.0 million during Q1 2022, with a 5-year trough of -$12.3 million in Q3 2025.
- Its 5-year average for Common Equity is $60.1 million, with a median of $50.4 million in 2021.
- Its Common Equity has fluctuated over the past 5 years, first soared by 38621.83% in 2021, then crashed by 17927.92% in 2025.
- Quarter analysis of 5 years shows Oncology Institute's Common Equity stood at $104.2 million in 2021, then increased by 18.26% to $123.2 million in 2022, then crashed by 53.7% to $57.0 million in 2023, then tumbled by 93.71% to $3.6 million in 2024, then plummeted by 441.99% to -$12.3 million in 2025.
- Its Common Equity stands at -$12.3 million for Q3 2025, versus -$9.0 million for Q2 2025 and $5.1 million for Q1 2025.